Left ventricular assist device (LVAD) implantation has become a mainstay of therapy for advanced heart failure patients who are either ineligible for, or awaiting, cardiac transplantation. Controversy remains over the optimal therapeutic strategy for preexisting aortic valvular dysfunction in these patients at the time of LVAD implant. In patients with moderate to severe aortic regurgitation, surgical approaches are center specific and range from variable leaflet closure techniques to concomitant aortic valve replacement (AVR) with a bioprosthesis. In the present study, we retrospectively analyzed our outcomes in patients who underwent simultaneous AVR and LVAD implantation secondary to antecedent aortic valve pathology. Between January 2004 and June 2010, 144 patients underwent LVAD implantation at a single institution. Of these, 7 patients (4.8%) required concomitant AVR. Five of the 7 patients (71%) survived to hospital discharge and suffered no adverse events in the perioperative period. One-year survival for the discharged patients was 80%, and no prosthetic valve-related adverse events were observed in long-term follow-up. Given our experience, we conclude that bioprosthetic AVR is a plausible alternative for end-stage heart failure patients at the time of LVAD implantation. C ontinuous fl ow pump technology has revolutionized long-term ventricular assist device therapy. Results from the HeartMate II trial show a considerable improvement in both survival and quality of life in recipients of this technology (1, 2). A proportion of these patients have associated aortic regurgitation (AR) that if left untreated may progress and impact the eff ectiveness of the pump by limiting forward fl ow (3). Th ere are several methods of managing AR at the time of left ventricular assist device (LVAD) implantation. Each has its own merits and fl aws. Techniques include patch closure of the outfl ow tract (4), primary aortic cuspal closure with felt strips (5), coaptation stitching of the valve cusps (6), and aortic valve replacement (7). Since our initial experience with the HeartMate II device, we have treated patients with signifi cant AR at the time of HeartMate II implantation by replacing the aortic valve with a bioprosthesis. Th is report describes the outcomes associated with this approach.
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METHODS
A retrospective review of end-stage heart failure patients who had undergone LVAD implantation with the HeartMate II continuous fl ow pump with concomitant aortic valve replacement at a single institution was conducted. Etiology of heart failure encountered in this study included ischemic and valvular cardiomyopathies. Th e latter was defi ned as end-stage heart failure secondary to untreated aortic or mitral valve disease. Medical records provided demographic and echocardiographic information as well as short-and long-term outcomes. Th is study was conducted with the approval of the institutional review board of the Cleveland Clinic.
All procedures were performed through a full median sternotomy. Aortic valve replacements preceded pump implantations. A pump pocket for the HeartMate II was initially created, and subsequently patients were heparinized and cannulated. With an appropriate activated clotting time (>400 seconds), patients were placed on cardiopulmonary bypass. Myocardial protection was achieved using intermittent cold blood cardioplegia.
Aortic valves were replaced through a hockey stick aortotomy. Once the valve was excised, an appropriate-sized bioprosthesis was selected and sutured into place with horizontal mattress pledgeted sutures placed on the ventricular side of the annulus. As described previously, 'annulus' was defi ned as the virtual, circular ring delineated by the nadirs of the semilunar leafl et attachments (8) . Th e aortotomy was closed and the LVAD implanted. In all cases the outfl ow graft was anastomosed to the ascending aorta distally beyond the suture line employed for the valve replacement.
Th e anticoagulation regimen for patients receiving a HeartMate II device consisted of warfarin, dipyridamole, and aspirin. Early in our experience with the HeartMate II, the target international normalized ratio (INR) ranged from 2.0 to 3.0. More recently, given the current understanding of the physiologic alterations in the coagulation system that occur with this device, we have targeted an INR of 1.7 to 2.5. Immediately
Replacement of the aortic valve with a bioprosthesis at the time of continuous flow ventricular assist device implantation for preexisting aortic valve dysfunction Brian Lima, MD, Themistokles Chamogeorgakis, MD, Maria Mountis, MD, and Gonzalo V. Gonzalez-Stawinski, MD postoperatively, the speed of the pump was set between 8200 and 8800 revolutions per minute (rpm). Th is allowed for easier hemodynamic management in the immediate postoperative period because of fl uid shifts encountered in the fi rst few days following HeartMate II implantation. Th e speed typically was adjusted so that there was adequate left ventricular unloading and midline septal alignment, with the aortic valve opening at every third cardiac beat. For patients who underwent aortic valve replacement, we attempted to adjust the pump's rpm so that the valve opened with every beat. Th ese adjustments were typically conducted with echocardiographic assistance.
RESULTS
Between January 2004 and June 2010, 144 patients underwent implantation of a HeartMate II at the Cleveland Clinic for the management of end-stage heart disease. Among these, 7 (4.8%) underwent concomitant aortic valve replacement (Table) . Indications for HeartMate II support included valvular cardiomyopathy (n = 4) and ischemic cardiomyopathy (n = 3). Th e end goal for LVAD therapy was destination therapy in fi ve patients and bridge-to-transplantation in two. Indications for aortic valve replacement included four cases of pure AR, one case of mixed AR and aortic stenosis, one case of aortic stenosis, and one case of an in situ mechanical aortic valve prosthesis that needed to be exchanged for a bioprosthesis.
Five of seven patients (71%) survived to discharge and suff ered no adverse events during their hospitalization. Two perioperative deaths occurred at 6 and 9 days, respectively. Th ese included one patient who underwent a primary aortic valve replacement and HeartMate II implantation. Th is patient succumbed to severe and refractory vasoplegia, a form of vasodilation not associated with sepsis or neurologic etiologies. Another patient had undergone a redo sternotomy with aortic and mitral valve exchanges from mechanical to bioprosthetic valves, as well as tricuspid valve repair and HeartMate II implantation. Th is patient died of severe pulmonary dysfunction secondary to acute respiratory distress syndrome and multisystem organ failure. At autopsy, both bioprosthetic valves were well seated with no evidence of thrombus formation.
At last follow-up, four of the fi ve patients were alive and well. One patient died of sepsis after 99 days of support. Echocardiographic examination of the bioprosthetic valve prior to the patient's demise suggested that the valve was well seated with no evidence of thrombus or pannus formation. An autopsy was not performed.
Th e remaining patients had no thromboembolic complications at a mean length of support of 395 days (range, 159 to 711). Echocardiographic examination of these patients revealed valves that were well seated with no evidence of thrombosis or pannus formation. Bioprosthetic valves in two destination therapy patients (time on support 391 days and 711 days) intermittently opened on examination. Two other patients underwent transplantation at 159 and 421 days of support. Th eir echocardiograms showed well-seated bioprosthetic valves that were not opening, with no thrombus or pannus deposited around the valve. Examination of the valves in explanted hearts revealed well-seated valves, without cuspid fusion or cusped thrombi. However, in the patient who was supported 159 days, the left ventricular outfl ow tract was completely open, while in the one supported for 421 days a fi brous membrane completely occluded the undersurface of the valve.
DISCUSSION
Th e optimal management of patients with coexisting AR at the time of continuous fl ow pump LVAD implantation is not well established. Several options exist, each with its own advantages and disadvantages. Supporters of valve procedures aimed at closing the ventricular outfl ow with either patch coverage of the valve or leafl et closure suggest that these approaches may theoretically decrease the risk of pump, aortic valve, or subaortic valve thrombus formation by directing fl ow entirely through the pump (5, 9) . Concerns raised by this approach include the mandatory dependence on the pump, which, if it were to malfunction, would potentially be lethal if the ventricle had not recovered to accommodate a high regurgitant backfl ow. Additionally, these approaches may be applicable only to patients who are transplant candidates, not to patients in whom recovery may be possible. Others suggest treating AR with a coaptation stitch of the leafl ets (Park's stitch) (6) . Diff erent from outfl ow closure techniques, this approach permits partial fl ow through the root, which may prevent thrombus formation while treating the AR. A second benefi t of this technique is that it does not render the patient's circulation completely LVAD dependent. Issues associated with this approach lie in the potential for valve pathology progression, disruption of the repair causing severe AR, and unknown long-term success (10) . Similar to ventricular outfl ow closure, this technique may not be applicable to those in whom left ventricular recovery is possible.
Bioprosthetic valve replacement has the advantage of eliminating valve pathology altogether while not rendering the patient LVAD dependent. If patients are allowed to eject through the valve with some frequency during the cardiac cycle, thrombus formation and leafl et fusion may be prevented. Valve replacement with a bioprosthesis may be a better approach for patients who are recovery candidates, because the LVAD may be explanted without the need to add a valve procedure. Th e concern of this approach is subvalvular obstruction, which may occur as a result of stagnant blood underneath the bioprosthetic valve (7, 11, 12) . Th rombus in this location may embolize during the cardiac cycle or alternatively mature into a fi brous membrane obstructing the outfl ow tract. Th e latter event, as seen in one of our patients, may be diffi cult to detect by standard screening techniques such as echocardiography.
Th rombus/pannus formation is not a universal occurrence following valve replacement with a bioprosthesis. Certainly we do not believe that this event is happening in those patients whose valves are intermittently opening while on support, but it may occur, particularly with longer support times. A second issue associated with valve replacement therapy is the added cost incurred when replacing the valve. Furthermore, the time spent replacing the valve may add morbidity to an already complicated procedure.
When to replace an incompetent valve may be a challenging decision. Th e decision has to be balanced not only with the degree of AR but also the objective for which the LVAD is used. For patients awaiting transplantation who have mild to moderate AR and a short waiting time, replacing the valve may not be necessary. Conversely, for patients who are destination therapy candidates who have anything greater than trivial AR (+1 or greater), addressing the valve at the time of LVAD implant seems reasonable.
Based on our experience and previously published reports, we believe that a tailored approach to AR at the time of LVAD implantation is warranted. For patients who have a foreseeable short support time, such as bridge-to-transplantation or frail patients, it seems reasonable to treat AR with any one of the coaptation or patch techniques previously described. However, for patients in whom recovery is possible, long-term destination therapy patients, and those with extremely friable aortic valves, aortic valve replacement with a bioprosthetic valve may be a better option. Limitations of this study include the small number of patients, the short follow-up, and the retrospective nature of this report.
